156 related articles for article (PubMed ID: 2537566)
1. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure.
Stone CK; Uretsky BF; Linnemeier TJ; Shah PK; Amin DK; Snapinn SM; Rush JE; Langendörfer A; Liang CS
Am J Cardiol; 1989 Mar; 63(9):567-70. PubMed ID: 2537566
[TBL] [Abstract][Full Text] [Related]
2. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses.
Uretsky BF; Shaver JA; Liang CS; Amin D; Shah PK; Levine TB; Walinsky P; LeJemtel T; Linnemeier T; Rush JE
Am Heart J; 1988 Aug; 116(2 Pt 1):480-8. PubMed ID: 2840815
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure.
Dickstein K
J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S73-81. PubMed ID: 2442558
[TBL] [Abstract][Full Text] [Related]
4. Lisinopril for severe congestive heart failure.
Uretsky BF; Shaver JA; Liang CS; Amin D; Shah PK; Levine TB; Walinsky P; LeJemtel T; Linnemaier T
Am J Cardiol; 1989 Feb; 63(8):8D-11D. PubMed ID: 2537565
[TBL] [Abstract][Full Text] [Related]
5. Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure.
Dickstein K; Aarsland T; Woie L; Abrahamsen AM; Fyhrquist F; Cummings S; Gomex HJ; Hagen E; Kristianson K
Am Heart J; 1986 Jul; 112(1):121-9. PubMed ID: 3014850
[TBL] [Abstract][Full Text] [Related]
6. Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.
Woie L; Dickstein K; Kaada B
Gen Pharmacol; 1987; 18(6):577-87. PubMed ID: 2822521
[TBL] [Abstract][Full Text] [Related]
7. Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure.
Bellissant E; Annane D; Pussard E; Thuillez C; Giudicelli JF
Fundam Clin Pharmacol; 1996; 10(2):127-35. PubMed ID: 8737955
[TBL] [Abstract][Full Text] [Related]
8. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations.
DiCarlo L; Chatterjee K; Parmley WW; Swedberg K; Atherton B; Curran D; Cucci M
J Am Coll Cardiol; 1983 Nov; 2(5):865-71. PubMed ID: 6313787
[TBL] [Abstract][Full Text] [Related]
9. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
10. A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure.
Insel J; Mirvis DM; Boland MJ; Cinquegrani MP; Shanes J; Rubin SA; Whalen JJ
Clin Pharmacol Ther; 1989 Mar; 45(3):312-20. PubMed ID: 2537699
[TBL] [Abstract][Full Text] [Related]
11. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension.
Garavaglia GE; Messerli FH; Nunez BD; Schmieder RE; Frohlich ED
Am J Cardiol; 1988 Nov; 62(13):912-6. PubMed ID: 2845768
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure.
Levine TB; Olivari MT; Garberg V; Sharkey SW; Cohn JN
Circulation; 1984 Mar; 69(3):548-53. PubMed ID: 6319045
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect.
Garavaglia GE; Messerli FH; Nunez BD; Schmieder RE; Frohlich ED
Am J Hypertens; 1988 Jul; 1(3 Pt 3):214S-216S. PubMed ID: 2843195
[TBL] [Abstract][Full Text] [Related]
14. Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.
Kukin ML; Freudenberger RS; Mannino MM; Kalman J; Steinmetz M; Buchholz-Varley C; Ocampo ON
Am Heart J; 1999 Aug; 138(2 Pt 1):261-8. PubMed ID: 10426837
[TBL] [Abstract][Full Text] [Related]
15. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.
De Marco T; Daly PA; Liu M; Kayser S; Parmley WW; Chatterjee K
J Am Coll Cardiol; 1987 May; 9(5):1131-8. PubMed ID: 3033043
[TBL] [Abstract][Full Text] [Related]
16. Acute haemodynamic effects of lisinopril and captopril in patients with severe congestive heart failure.
Van Mieghem W; Van Hedent T; Byttebier G
Acta Cardiol; 1993; 48(1):43-53. PubMed ID: 8383397
[TBL] [Abstract][Full Text] [Related]
17. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.
Hall D; Zeitler H; Rudolph W
J Am Coll Cardiol; 1992 Dec; 20(7):1549-55. PubMed ID: 1452929
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure.
Cody RJ; Covit AB; Schaer GL; Laragh JH
J Am Coll Cardiol; 1983 Apr; 1(4):1154-9. PubMed ID: 6187789
[TBL] [Abstract][Full Text] [Related]
19. Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure.
Levine TB; Cohn JN
Am Heart J; 1982 Nov; 104(5 Pt 2):1159-64. PubMed ID: 6182784
[TBL] [Abstract][Full Text] [Related]
20. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada.
Parker AB; Azevedo ER; Baird MG; Smith SJ; Arnold JM; Humen DP; Moe GW; Parker JO; Butt RW; Parker JD
Am Heart J; 1999 Nov; 138(5 Pt 1):843-8. PubMed ID: 10539814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
